Clinical trial · Interventional
MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex
NCT01450397CI-TRIAL-00027034completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effects of XIAFLEX on your finger through MRI.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dupuytren's Disease | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| XIAFLEX | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- XIAFLEX
- description
- XIAFlEX
- interventionNames
- Biological: XIAFLEX
Primary outcomes (1)
- measure
- The Measured Change in Volume of the Cord by MRI Before and After XIAFLEX Injection and Manual Manipulation.
- timeFrame
- Baseline and 30 days
- description
- Change in Volume (millimeter cubed) of the Cord by MRI between Baseline and 30 days after XIAFLEX injection and manual manipulation.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Subject has a diagnosis of Dupuytren's Disease affecting only the metacarpophalangeal joint of the 4th or 5th finger. * Subject has only one finger affected by the disease. * Patients will be 35 years of age of older. * Patients will be able to read, speak, and understand English or have available adequate translation assistance and be able to provide voluntary written consent to participate. Exclusion Criteria: * Female patients who are nursing or pregnant, or plan to become pregnant during the treatment phase. * Patient has a chronic muscular, neurological or neuromuscular disorder that affects the hands. * Patient has known allergy to collagenase or any other excipient of Xiaflex. * Patient has received any collagenase treatments before the first dose of Xiaflex. * Patient with abnormal coagulation, including patients who have received anticoagulant medications other than low-dose aspirin within 7 days of the injection.
References
Publications (0)
Data not yet available
No reference posted for this study.